The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer

According to studies, 25-66% of patients with metastatic highly differentiated thyroid cancer (DTC) develop partial or complete resistance of metastases to therapy with radioactive iodine. The review discusses the molecular mechanisms for the involvement of various apoptosis proteins in the formation of radioiodine resistance in patients with DTC, as well as the molecular mechanisms of the action of multikinase inhibitors, with a range of therapeutic effects from complete tumour regression to stabilization, on apoptosis. Considering the literature on the ambiguous role of apoptosis in the formation of radioiodine resistance in DTC, required further examination of its molecular mechanisms, its relationship with such a process as autophagy, the effect of multikinase inhibitors on its molecular basis and on overcoming iodine resistance. Studying the mechanism of apoptosis regulations gives a chance to find new targeted aims exposure in its individual stages in order to regulate or correct them.

Download Full-text

The role of radioiodine SPECT/CT in differentiated thyroid cancer

Endocrine Abstracts ◽

10.1530/endoabs.32.p1097 ◽

2013 ◽

Author(s):

Emese Mezosi ◽

Laszlo Bajnok ◽

Karoly Rucz ◽

Csaba Weninger ◽

Erzsebet Schmidt ◽

...

Keyword(s):

Thyroid Cancer ◽

Differentiated Thyroid Cancer

Download Full-text

The role of preoperative serum thyroglobulin values in the diagnosis of differentiated thyroid cancer

Endocrine Abstracts ◽

10.1530/endoabs.49.ep1370 ◽

2017 ◽

Author(s):

Blertina Dyrmishi ◽

Taulant Olldashi ◽

Ema Lumi ◽

Entela Puca ◽

Dorina Ylli ◽

...

Keyword(s):

Thyroid Cancer ◽

Differentiated Thyroid Cancer ◽

Serum Thyroglobulin ◽

Preoperative Serum

Download Full-text

The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer

Annals of Nuclear Medicine ◽

10.1007/s12149-021-01644-1 ◽

2021 ◽

Author(s):

Domenico Albano ◽

Francesco Dondi ◽

Valentina Zilioli ◽

Maria Beatrice Panarotto ◽

Alessandro Galani ◽

...

Keyword(s):

Thyroid Cancer ◽

Treatment Response ◽

Differentiated Thyroid Cancer ◽

Hashimoto Thyroiditis ◽

Prognostic Impact ◽

Intermediate Risk ◽

Excellent Response ◽

Radioiodine Ablation ◽

One Year

Abstract Objective The baseline treatment of differentiated thyroid cancer (DTC) consists of thyroidectomy followed by postoperative risk-adapted radioiodine therapy (RAIT) when indicated. The choice of most appropriate RAI activities to administer with the aim to reach an efficient remnant ablation and reduce the risk of recurrence is yet an open issue and the detection of basal factors that may predict treatment response seems fundamental. The aim of this study was to investigate the potential role of Hashimoto thyroiditis (HT) in predicting 1-year and 5-year treatment response after RAIT and prognosis. Methods We retrospectively included 314 consecutive patients (174 low-risk and 140 intermediate-risk) who received thyroidectomy plus RAIT. One-year and 5-year disease status was evaluated according to 2015 ATA categories response based upon biochemical and structural findings. Results HT was reported histopathologically in 120 patients (38%). DTC patients with concomitant HT received a higher number of RAITs and cumulative RAI activities. Initial RAIT reached an excellent response in 63% after one year and 84% after 5 years. The rate of excellent response one year and 5-year after first RAIT was significantly lower in HT groups, compared to not HT (p < 0.001). Instead, HT did not have a prognostic role considering PFS and OS; while stimulate thyroglobulin (sTg) at ablation was significantly related to survival. Conclusions HT may affect the efficacy of RAIT in low to intermediate risk DTC, particularly reducing the successful rate of excellent response after RAIT. Instead, HT did not have a prognostic impact such as stimulated sTg.

Download Full-text